GT
ESPR

Glenmede Trust’s Esperion Therapeutics ESPR Stock Holding History

Glenmede Trust’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,071
Closed -$209K – 1212
2020
Q4 		$209K Sell
8,071
-4,120
-34% -$123K ﹤0.01% 1048
2020
Q3 		$453K Buy
12,191
+3,060
+34% +$121K ﹤0.01% 817
2020
Q2 		$468K Sell
9,131
-1,065
-10% -$44.6K ﹤0.01% 779
2020
Q1 		$607K Hold
10,196
– – ﹤0.01% 852
2019
Q4 		$607K Buy
+10,196
New +$458K ﹤0.01% 852
2016
Q3 		– Sell
-500
Closed -$4K – 2606
2016
Q2 		$4K Buy
+500
New +$8.29K ﹤0.01% 2275

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Glenmede Trust's ESPR Position: Q1 2021 in Review

Glenmede Trust sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 8,071 shares — an estimated $209K sold.

Glenmede Trust first reported a position in ESPR in Q2 2016 and held it in 6 quarters. The position peaked at $607K in Q1 2020. 155 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

  • Glenmede Trust reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Glenmede Trust sold 8,071 Esperion Therapeutics shares in Q1 2021, an estimated $209K.
  • Glenmede Trust first reported a position in Esperion Therapeutics in Q2 2016 and held it in 6 quarters.
  • Glenmede Trust's Esperion Therapeutics position peaked at $607K in Q1 2020.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on Glenmede Trust's 13F filing for Q1 2021, filed 18 May 2021.